Switching elderly chronic psychotic patients to olanzapine

International Journal of Neuropsychopharmacology

Volumn 7, Issue 2, 2004, Pages 165-169

  Barak, Yoram ^a,d   Shamir, Eyal ^a,d   Mirecki, Ilona ^a,d   Weizman, Ronit ^b,d   Aizenberg, Dov ^c,d  

^a ABARBANEL MENTAL HEALTH CENTER   (Israel)

^b TEL AVIV COMMUNITY MENTAL HEALTH CENTER   (Israel)

^c GEHA MENTAL HEALTH CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Elderly; Olanzapine; Psychosis; Switch

Indexed keywords

ANTIDIABETIC AGENT; BENZODIAZEPINE DERIVATIVE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; HUMAN; MALE; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZODIAZEPINES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

EID: 3042619843     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145703004048     Document Type: Article

References (26)

1. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry 156, 1686-1696.
2. Almeida OP, Almeida SA (1999). Short versions of the geriatric depression scale: a study of their validity for the diagnosis of a major depressive episode according to ICD-10 and DSM-IV. International Journal of Geriatric Psychiatry 14, 858-865.
3. Altamura AC, Curreli R (1998). Antipsychotics in the elderly: the use of 'typical' vs. 'atypical' compounds. In: Brunello N, Langer SZ, Racagni G (Eds.), Mental Disorders in the Elderly: New Therapeutic Approaches (pp. 123-138). Basel: Karger.
4. Barak Y, Shamir E, Weizman R (2002a). Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study. Journal of Clinical Psychopharmacology 22, 115-120.
5. Barak Y, Shamir E, Zemishlani H, Mirecki I, Toren P, Weizman R (2002b). Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients. Progress in Neuropsychopharmacology and Biological Psychiatry 26, 1199-2202.
6. Callahan AM, Fava M, Rosenbaum JF (1993). Drug interactions in psychopharmacology. Psychiatric Clinics of North America 16, 647-671.
7. Chan Y, Pariser SF, Neufeld G (1999). Atypical antipsychotics in older adults. Pharmacotherapy 19, 811-822.
8. Davidson M, Harvey P, Welsh KA, Powchik P, Putnam KM, Mohs RC (1996). Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease. American Journal of Psychiatry 153, 1274-1279.
9. Gordon M, Preiksaitis HG (1988). Drugs and the aging brain. Geriatrics 43, 69-78.
10. Guy W (Ed.) (1976). ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare.
11. Kay SR, Opler LA, Lindenmayer JP (1988). Relaiability and validity for the Positive and Negative Syndrome Scale for schizophrenics. Psychiatry Research 23, 99-110.
12. Kumar V, Brecher M (1999). Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. Journal of Clinical Psychiatry 60 (Suppl. 13), 5-9.
13. Lacro JP, Eastham JH, Jeste DV, Lohr JB (1996). Newer antipsychotics and antidepressants for elderly people. Current Opinion in Psychiatry 9, 290-293.
14. Leucht A, Pitschel-Waltz G, Abraham D (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68.
15. Madhusoodanan S, Brenner R, Suresh P, Concepcion NM, Florita CD, Menon G, Kaur A, Nunez G, Reddy H (2000). Efficacy and tolerability of olanzapine in elderly patients with psychotic disorders: a prospective study. Annals of Clinical Psychiatry 12, 11-18.
16. Madhusoodanan S, Sinha S, Brenner R, Gupta S, Bogunovic O (2001). Use of olanzapine for elderly patients with psychotic disorders: a review. Annals of Clinical Psychiatry 13, 201-213.
17. Madhusoodanan S, Suresh P, Brenner R, Pillai R (1999). Experience with the atypical antipsychotics - risperidone and olanzapine in the elderly. Annals of Clinical Psychiatry 11, 113-118.
18. Ortega RM, Andres P (1998). Is obesity worth treating in the elderly? Drugs and Aging 12, 97-101.
19. Procyshyn RM, Zerjav S (1998). Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics 20, 1203-1217.
20. Rabinowitz J, Lichtenberg P, Kaplan Z (2000). Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophrenia Research 46, 91-96.
21. Reid J (1985). Medication compliance in the elderly: a review. Journal of Clinical and Experimental Gerontology 7, 31-49.
22. Sajatovic M, Perez D, Brescan D, Ramirez LF (1998). Olanzapine therapy in elderly patients with schizophrenia. Psychopharmacology Bulletin 34, 819-823.
23. SAS/STAT (1990). Users' Guide, Version 6 (4th edn), vols 1, 2. Cary, NC: SAS Institute.
24. Solomons K, Geiger O (2000). Olanzapine use in the elderly: a retrospective analysis. Canadian Journal of Psychiatry 45, 151-155.
25. Taylor D, Aitchinson KJ (1999). The pharmaco-economics of atypical antipsychotics. International Journal of Psychiatry and Clinical Practice 3, 237-248.
26. Zarate CA, Baldessarini RJ, Siegel AJ, Nakamura A, McDonald J, Muir-Hutchinson LA, Cherkerzian T, Tohen M (1997). Risperidone in the elderly: a pharmacoepidemiologic study. Journal of Clinical Psychiatry 58, 311-317.